Reversal of triazolam- and zolpidem-induced memory impairment by flumazenil
| Autor: | Nancy J. Wesensten, T. J. Balkin, H. Q. Davis, Gregory Belenky |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Flumazenil Male Volunteers Zolpidem Triazolam Time Factors Adolescent medicine.drug_class Pyridines Administration Oral Pharmacology Placebo Hypnotic Memory medicine Memory impairment Humans Hypnotics and Sedatives Memory disorder Benzodiazepine business.industry medicine.disease Placebo Effect Anesthesia business medicine.drug |
| Zdroj: | Psychopharmacology. 121(2) |
| ISSN: | 0033-3158 |
| Popis: | The effects of flumazenil, a benzodiazepine receptor antagonist, on triazolam- and zolpidem-induced memory impairment were investigated. Sixty subjects received oral triazolam 0.5 mg, zolpidem 20.0 mg, or placebo at 10 a.m. (n = 20 per drug). Ninety minutes later, half of the subjects (n = 10) in each oral drug group were administered flumazenil 1.0 mg, while the remaining half received placebo (normal saline), through indwelling venous catheters. Learning/memory tests (including Simulated Escape, Restricted Reminding, Paired-Associates, and Repeated Acquisition) were administered at that time, and at 1.5-h intervals over the next 6 h. Triazolam/placebo and zolpidem/placebo drug combinations impaired memory on all tests (all Ps0.05). However, the triazolam/flumazenil and zolpidem/flumazenil groups showed no evidence of impairment during any test session. These results demonstrate that flumazenil 1.0 mg rapidly and lastingly reverses memory impairment caused by agonists of the benzodiazepine receptor. Furthermore, nonsignificant trends suggested that performance of the placebo/flumazenil group was consistently better than that of the placebo/placebo group, denoting a possible role of endogenous benzodiazepine agonists in natural sleep/wake processes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink